Results 91 to 100 of about 10,402 (207)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma

, 2009
Jatin J Shah1, Robert Z Orlowski1,2, Sheeba K Thomas11Departments of Lymphoma/Myeloma; 2Experimental Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: The first in class proteasome ...
Sheeba K Thomas, Jatin J Shah, Robert Z Orlowski   +2 more
core  

USING PHARMACOECONOMIC MODELLING TO DETERMINE VALUE-BASED PRICING FOR NEW MEDICINES

Кубанский научный медицинский вестник, 2017
Purpose: to carry out pharmacoeconomic modeling for an early economic evaluation of the generic pegylated liposomal doxorubicin (PLD) drug.Materials and methods: a Markov model and Decision tree model were developed to simulate and to compare the costs ...
I. S. KRYSANOV, V. Yu. ERMAKOVA, A. V. ZABOROVSKY, K. G. GUREVICH   +3 more
doaj   +1 more source

Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer

, 2008
Breast cancer incidence is increasing among elderly patients. Age is a risk factor for toxicity after chemotherapy for breast cancer. In particular, anthracycline-induced cardiac toxicity is increased in elderly patients.
Minisini AM, Andreetta C, PUGLISI, Fabio, Fasola G   +3 more
core   +1 more source

Pegylated Liposomal Doxorubicin and Gemcitabine in Patients With Advanced Hepatocellular Carcinoma Results of a Phase 2 Study [PDF]

, 2011
BACKGROUND: Over the years, doxorubicin and gemcitabine have been among the most widely used drugs for hepatocellular carcinoma (HCC), with relative efficacy.
VITALE A, LOMBARDI, GIUSEPPE, ZANUS G, CILLO, UMBERTO, PASTORELLI D., DONACH M, FARINATI, FABIO, ZUSTOVICH F, ZOVATO S, FARINA M   +9 more
core   +1 more source

Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer

, 2014
Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast ...
Cold, Soeren, Eva Balslev (835794), Malgorzata K. Tuxen (835835), Nielsen, D. L., Balslev, E., Tange, Ulla B, Tuxen, Malgorzata K, Cold, S., Tange, U. B., Soeren Cold (835836), Ulla B. Tange (835837), Nielsen, Dorte L, Dorte L. Nielsen (579682), Tuxen, M. K., Balslev, Eva   +14 more
core   +1 more source

Pegylated liposomal doxorubicin in ovarian cancer.

International journal of nanomedicine, 2007
Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers.
Andrew E, Green, Peter G, Rose
openaire   +1 more source

Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer [PDF]

, 2017
Combination of anthracyclines with trastuzumab is hampered by cardiotoxicity. Pegylated liposomal doxorubicin and lapatinib could represent a safer alternative to combination therapy.In this phase Ib study with 3 + 3 dose escalation design, patients with
Elisabetta Pietri, Monti, Manuela, Dino Amadori, Caterina Donati, Rocca, Andrea, Pietri, Elisabetta, Lorenzo Cecconetto, Daniele Andreis, Faedi, Marina, Donati, Caterina, Marina Faedi, Melegari, Elisabetta, Manuela Monti, Passardi, Alessandro, Maltoni, Roberta, Nanni, Oriana, Roberta Maltoni, Francesco Fabbri, Fabbri, Francesco, Schirone, Alessio, Sarti, Samanta, Amadori, Dino, Oriana Nanni, Anna Fedeli, Alessandro Passardi, Alessio Schirone, Fedeli, Anna, Andrea Rocca, Cecconetto, Lorenzo, Elisabetta Melegari, Samanta Sarti, Andreis, Daniele   +31 more
core   +1 more source

Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer

Scientific Reports
This study investigates the efficacy and toxicity profiles of pegylated liposomal doxorubicin (Doxil) compared to conventional doxorubicin. Additionally, it evaluates the potential of combination therapy involving Doxil and doxorubicin with aprepitant ...
Atefeh Ghahremanloo, Bahareh Erfani, Fereshteh Asgharzadeh, Saeide Mansoori, Fatemeh Gheybi, Seyed Isaac Hashemy   +5 more
doaj   +1 more source

Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis

Experimental Hematology & Oncology, 2012
Background Liposomal formulations of anthracyclines appear to have favorable toxicity profile when compared with conventional anthracyclines in elderly, high risk cardiac patients and patients with prior use of anthracyclines.
Rafiyath Shamudheen M, Rasul Mohammad, Lee Byung, Wei Guoqing, Lamba Gurpreet, Liu Delong   +5 more
doaj   +1 more source

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.

, 1998
PURPOSE Cytotoxic chemotherapy is frequently required for the more severe manifestations of human immunodeficiency virus (HIV)-related Kaposi's sarcoma.
S Stewart, K Arasteh, J Galleshaw, H Jablonowski, D Aboulafia, A Rios, B J Dezube, F D Goebel, M Spittle   +8 more
core   +1 more source